Mizuho has adjusted its price target for ResMed (RMD, Financial), bringing it down to $250 from the previous $265. Despite this revision, the investment firm maintains an Outperform rating for the company's shares.
ResMed recently released its fiscal third-quarter results, which aligned with market expectations. According to Mizuho, the company faces minimal impact from tariff changes, as it is positioned advantageously regarding these trade concerns.
The firm's analysis also notes that ResMed does not currently experience any significant negative influence from GLP-1 drug competition. This suggests that the company remains robust in its market strategy and product offerings.
